China Clears HIV Oral Antiviral For COVID, Vows More Drug Approvals
Executive Summary
As the Communist Party of China gears up for its once in every five years National Congress late this fall, the need for more novel drugs to help address the persistent coronavirus pandemic is rising amid the country’s strict “COVID Zero” policies.
You may also be interested in...
Chinese-Language Podcast: 聊聊七月生物制药热门话题
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
China Cool On Nasal Vaccines, Backs Antivirals In Latest COVID Guidance
China’s Center for Drug and Evaluation has issued new guidance on the development of new vaccines and drugs for COVID-19 in which it backs antivirals as a key weapon, while the Politburo has shown no signs of backing away from the country's tough "COVID Zero" policies.
Japan Again Postpones Approval Of Shionogi COVID Antiviral
Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.